European Active Surveillance Study of LCS12 (EURAS_LCS12)

April 20, 2026 updated by: Center for Epidemiology and Health Research, Germany
This study is designed to investigate whether LCS12 is associated with an increased risk of unintended pregnancy compared to Mirena and to copper IUDs. The objective is to assess among new users the risks of certain events (e.g. contraceptive failure rate, ectopic pregnancy, uterine perforation, and PID) associated with the use of LCS12 compared with the established hormonal IUD Mirena, and compared with established copper IUDs during standard clinical practice. In addition, drug utilization patterns will be described.

Study Overview

Status

Active, not recruiting

Conditions

Detailed Description

Intrauterine contraceptive methods, such as Mirena and copper IUDs, have a high contraceptive efficacy. LCS12 is a new intrauterine system which, like Mirena, contains levonorgestrel (LNG), but the T-body dimensions and insertion tube diameter of LCS12 are smaller.

Because there is a lack of comparative data between LCS12 and other intrauterine contraceptives, it is unclear whether there are differences in contraceptive failure rates between LCS12 and either Mirena or copper IUDs. In addition, any transcervical procedure, including the insertion of an intrauterine device, is potentially associated with the risk of infection/inflammation.

EURAS-LCS12 is a prospective, controlled, non-interventional, active surveillance cohort study with three user cohorts: LCS12, Mirena and copper IUDs. Study participants will be recruited by a network of health care professionals and will be followed up through active surveillance to collect information regarding the outcomes of interest and major safety outcomes.

All self-reported clinical outcomes of interest will be validated by health care professionals. The primary endpoint is unintended pregnancy. Secondary endpoints are ectopic pregnancy, uterine perforation, and pelvic inflammatory disease (PID).

Study Amendment (Approved by PRAC on September 29, 2016):

The primary objective of the study is to assess the contraceptive failure risk of Jaydess, Mirena, and copper IUD use in a study population that is representative of the real users of the individual IUDs. Interim analysis showed a high proportion of IUD users in the age group >= 40 years of age. Given the fact that the age distribution remains considerably skewed, and that the Pearl Index is influenced by the age of participants, the independent Safety Monitoring and Advisory Council decided to suggest to narrow the study inclusion criteria, i.e. an age restriction to <40 years old at study entry was suggested for the remaining recruitment phase.

All analyses regarding unintended pregnancies (including ectopic pregnancies) will be conducted using the complete cohorts (i.e. including study participants aged 40 years and older). In addition, these analyses will be done including only women in the age group below 40 years. Further age-stratified analyses of these outcomes are also planned.

Study Amendment (Approved by PRAC in February, 2018):

In addition, due to concerns regarding the influence of the use of hormonal IUDs on neuropsychiatric disorders, the PRAC requested to investigate the baseline risk as well as the risk under exposure of IUDs within the EURAS-LCS12 study.

The baseline questionnaire will capture information on the history of anxiety, panic attacks, mood swings/depression, persistant difficulties with sleeping and restlessness (further on referred to as "neuropsychiatric complaints") for all newly recruited users after ethical approval of the revised questionnaire. Neuropsychiatric complaints that occur under exposure to an IUD reported by the study participant during the follow-up will be validated with the treating physician, if applicable, in the same manner as other outcomes of interest.

Furthermore, the study will be also conducted in Spain and Italy to be able to fulfil study goal in time, as the recruitment of Jaydess users is lower than expected due to the recent launch of another hormonal IUS (Kyleena) which is licensed for contraception for 5 years.

Study amendment (Approved by PRAC in October 2019):

In the course of the study, another hormonal IUD ( 'Kyleena') was launched in 2017 which has the same dimensions as LCS12, but a higher LNG content, and is approved for use up to 5 years. The initial LNG release rates are approximately 14 µg/24h for LCS12, 20 µg/24h for Mirena and 17.5 µg/24h for Kyleena. New users of Kyleena were continuously enrolled in the study since the market introduction and are categorized as 'other hormonal IUD'. However, with increasing usage of Kyleena and enrolment into the EURAS-LCS12 study, the Safety Monitoring and Advisory Council endorsed inclusion of Kyleena as an official cohort to the study to better understand current routine clinical practice. As comparative data on contraceptive failure between Kyleena and Mirena based on routine clinical practice are not available at present, the comparison of contraceptive failure rates between Kyleena and Mirena / copper IUDs was added as an additional secondary outcome to the EURAS-LCS12 study.

As the liscensed duration of use for Kyleena is 6 years, two additional follow-up questionnaires will be sent to eligible users of Kyleena, Mirena and copper IUDs to assess the complete life-cylce of the products.

Study amendment (Approved by PRAC in February 2022):

The purposes of this amendment no. 5 include an adaption of the timelines and recruitment target to allow for completion of the recruitment for the LCS12 cohort, and a merge of the final study report I (including LCS12 3-year results) and II (including Kyleena 5-year results). Further, the statistical methods used for confounder assessments will be adapted to address the imbalances between the cohorts. Finally, the inclusion of copper IUDs will be limited to 30% of current recruitment.

Study Type

Observational

Enrollment (Actual)

97265

Contacts and Locations

This section provides the contact details for those conducting the study, and information on where this study is being conducted.

Study Locations

  • Germany
      • Berlin, Germany, 10115
        • Center for Epidemiology and Health Research Berlin

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Eligibility Criteria

Ages Eligible for Study

No older than 39 years (Child, Adult)

Accepts Healthy Volunteers

Yes

Sampling Method

Non-Probability Sample

Study Population

Women using an intrauterine system/device (hormonal IUS or copper IUD)

Description

Inclusion Criteria:

  • Women aged below 40 years who have a new IUD inserted (LCS12, Kyleena, Mirena, copper IUD, or any other hormonal IUD)
  • Women who are willing to participate in the active surveillance

Exclusion Criteria:

  • Women aged 40 or older at insertion day
  • Women who are currently enrolled in an interventional trial on IUD use can not participate

Study Plan

This section provides details of the study plan, including how the study is designed and what the study is measuring.

How is the study designed?

Design Details

  • Observational Models: Cohort
  • Time Perspectives: Prospective

Cohorts and Interventions

Group / Cohort
LCS12
New users of LCS12
Mirena
New users of Mirena
Copper IUD
New users of copper IUDs
Kyleena
New users of Kyleena
Other hormonal IUD (OHIUD)
New users of other hormonal IUDs (e.g. Levosert, Fibroplant)

What is the study measuring?

Primary Outcome Measures

Outcome Measure
Time Frame
Contraceptive failure (LCS12 vs. Mirena and copper IUDs)
Time Frame: within 3 years
within 3 years

Secondary Outcome Measures

Outcome Measure
Time Frame
Pelvic inflammatory disease (PID)
Time Frame: within 3 - 5 years
within 3 - 5 years
Ectopic pregnancy
Time Frame: within 3 - 5 years
within 3 - 5 years
Uterine perforations
Time Frame: within 3 - 5 years
within 3 - 5 years
Contraceptive failure (Kyleena vs. Mirena and copper IUDs)
Time Frame: within 5 years
within 5 years

Collaborators and Investigators

This is where you will find people and organizations involved with this study.

Sponsor

Center for Epidemiology and Health Research, Germany

Collaborators

Bayer

Investigators

  • Principal Investigator: Klaas Heinemann, PhD, MD, MSc, MBA, Center for Epidemiology and Health Research Berlin

Publications and helpful links

The person responsible for entering information about the study voluntarily provides these publications. These may be about anything related to the study.

General Publications

Helpful Links

Study record dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Major Dates

Study Start (Actual)

June 17, 2014

Primary Completion (Estimated)

December 1, 2026

Study Completion (Estimated)

December 1, 2026

Study Registration Dates

First Submitted

May 22, 2014

First Submitted That Met QC Criteria

May 22, 2014

First Posted (Estimated)

May 26, 2014

Study Record Updates

Last Update Posted (Actual)

April 23, 2026

Last Update Submitted That Met QC Criteria

April 20, 2026

Last Verified

April 1, 2026

More Information

Terms related to this study

Keywords

Other Study ID Numbers

  • ZEG2013_10
  • 16470 (Other Identifier: Bayer AG)
  • EUPAS6476 (Registry Identifier: EUPAS Register)

This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.

Clinical Trials on Contraception

Search Similar Trials

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Cambodia

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations

Subscribe